Moreover, a pathogenic role of aberrant Rab5 is emerging in many of the same other neurodegenerative diseases that are being targeted by p38α inhibitor programs, including PD, DLB, ALS, and HD [71,72,73]. Here, RAB5A is linked to Huntington disease.